Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Glaucoma > Clustered testing approach may identify fast-progressing glaucoma
  • Glaucoma

Clustered testing approach may identify fast-progressing glaucoma

Kerri Fitzgerald
glaucoma progression

A clustered testing methodology detected fast-progressing glaucoma, indicating a potential approach for assessing high-risk individuals.

The prospective Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study took place at the Bascom Palmer Eye Institute at the University of Miami and the Duke Eye Center at Duke University. A total of 126 eyes from 65 patients (mean age, 68 years) with open-angle glaucoma were assessed. Patients underwent 2 clusters of testing consisting of 5 weekly visits at baseline and again approximately 6 months later. Patients continued cluster testing every 6 months for a mean duration of 25 months (mean, 17 tests total). Each visit consisted of testing with standard automated perimetry (SAP) 24-2 and 10-2, and spectral-domain optical coherence tomography (SD-OCT).

A total of 19 eyes (15%) progressed based on SAP 24-2 MD over the 6-month period. Median rates of change for progressors and non-progressors were –2.70 dB/year and 0.02 dB/year, respectively (P<.001).

A total of 14 eyes (11%) progressed on SAP 10-2 MD, and 16 eyes (13%) progressed by retinal nerve fiber layer thickness, with 30 eyes (24%) progressing by function, structure, or both.

Of the 35 eyes that progressed during overall follow-up, 25 did so during the 6-month cluster period (sensitivity, 71%). Of the 90 eyes that did not progress during overall follow-up, 85 did not progress during the 6 months (specificity, 94%).

Of the 14 eyes considered fast progressors by SAP 24-2, SAP 10-2, or SD-OCT during overall follow-up, 13 were identified as progressing during the 6-month cluster period (sensitivity, 93%; specificity, 85%).

The study is limited by its relatively smaller sample size. In addition, the authors indicated that patients who agreed to undergo intensive testing may have been more inclined to participate if they thought their disease could be worsening.

“Our intensive clustered testing methodology offers promising implications for clinical trials investigating interventions to slow down glaucoma progression. It may also be of value for short-term assessment of high-risk subjects,” the authors concluded.

Reference

Medeiros FA, Malek DA, Tseng H, et al. Short-term detection of fast progressors in glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study. Ophthalmology. 2023;S0161-6420(23)00938-7. doi:10.1016/j.ophtha.2023.12.031

Share

Related Content

  • Glaucoma

Expanding the glaucoma treatment landscape with FLIGHT technology

  • Glaucoma

Geographic differences in glaucoma care raise concerns about equitable access

  • Cataract

Optimizing cataract surgery outcomes through dry eye management

  • Cataract

Spotlight on TECNIS Odyssey™

  • Glaucoma

Study finds significant IOP reductions with iDose TR and MIGS procedures

  • Glaucoma

EyeValve device lowers IOP and maintains control for 9 months in first-in-human study

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon